490030-45-0

Basic information

• Product Name: 1-Piperazinecarboxylic acid, 4-[4-(trifluoromethoxy)phenyl]-, 1,1-dimethylethyl ester
• CAS NO: 490030-45-0
• Molecular Formula: C16H21F3N2O3
• Molecular Weight: 346.35
• Mol File: 490030-45-0.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-Piperazinecarboxylic acid, 4-[4-(trifluoromethoxy)phenyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazinecarboxylic acid, 4-[4-(trifluoromethoxy)phenyl]-, 1,1-dimethylethyl ester(490030-45-0)
• EPA Substance Registry System: 1-Piperazinecarboxylic acid, 4-[4-(trifluoromethoxy)phenyl]-, 1,1-dimethylethyl ester(490030-45-0)

Safety Data

• Hazardous Substances Data: 490030-45-0(Hazardous Substances Data)

Usage

Molecular weight

369.36 g/mol

Structure

An ester derivative of piperazinecarboxylic acid, containing a tert-butyl group and a trifluoromethoxyphenyl group.

Biological activity

Potential for biological activity due to its structure and functional groups.

Applications

Potential applications in pharmaceuticals and research, including the development of new drugs or as a research tool in the study of molecular interactions.

Further investigation needed

Additional research and testing is required to fully understand the properties and potential uses of this compound.

Upstream product

• 407-14-7 1-bromo-4-(trifluoromethoxy)benzene 
• 76144-87-1 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1426520-98-0 C₁₈H₂₀F₃N₃O 
• 1613627-52-3 C₁₈H₁₆F₃N₃O 
• 490030-46-1 1-(4-(trifluoromethoxy)phenyl)piperazine hydrochloride 
• 187669-62-1 1-(4-(trifluoromethoxy)phenyl)piperazine 

Relevant articles and documents

NOVEL VDAC1 INHIBITORS

The present invention relates to a compound of general formula I Wherein R1-7, Hy, and X are as defined in claim 1. Such compound of formula I binds to VDAC1 and is suitable for use in a method for treating diabetes or pre-diabetes in a subject

Methods for Treating Central Nervous System Disorders Using VDAC Inhibitors

The present invention relates to use of small organic compounds interacting with the Voltage-Dependent Anion Channel (VDAC) for the treatment of diseases associated with central nervous system (CNS) disorders, including psychotic disorders, mood disorders, neurodegenerative diseases. In particular the present invention relates to the use of substituted piperazine- and piperidine-derivatives and pharmaceutical compositions comprising same for the treatment of psychotic disorders including schizophrenia, mood disorders, and neurodegenerative diseases.

NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION

Provided herein piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction. Also provided methods of treatment of diseases associated with said processes, e.g. Alzheimer's disease.